
HONGSENG 0041
PREV | CLOSE | CHANGE | HIGH | CLOSE |
---|---|---|---|---|
1.170 | - | - | - | - |
VOLUME | BUY VOL | BUY | SELL | SELL VOL |
---|---|---|---|---|
- | 340 | 1.160 | 1.180 | 650 |
52 Weeks Range : 0.04 - 1.88
PREV | CLOSE | CHANGE | HIGH | CLOSE |
---|---|---|---|---|
1.170 | - | - | - | - |
VOLUME | BUY VOL | BUY | SELL | SELL VOL |
---|---|---|---|---|
- | 340 | 1.160 | 1.180 | 650 |
The Star –
Hong Seng Consolidated Bhd, via its wholly-owned subsidiary HS Bio Supplies Sdn Bhd, has acquired 51% stake in Pantasniaga Sdn Bhd, which has been supplying polymerase chain reaction (PCR) test kits for Covid-19. As Pantasniaga has already performed and fulfilled a few supply contracts for Malaysian government agencies, Hong Seng said HS Bio would be continuing its support to procure and supply the PCR test kits with the ongoing outbreak in Malaysia, as well as neighbouring countries.
REMUNERATION STUDY –
In Financial Year End 2020, the directors’ remuneration was 0.66 million. It was fair compared to average in listed companies, considering the employees’ remuneration of 2.7 million and auditor’s remuneration of 89 thousands
REMUNERATION STUDY –
In Financial Year End 2019, the directors’ remuneration was 1.02 million. It was fair compared to average in listed companies, considering the employees’ remuneration of 4.2 million and auditor’s remuneration of 108 thousands